[{"orgOrder":0,"company":"Atomwise","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Atomwise","sponsor":"FutuRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ FutuRx","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/ FutuRx"},{"orgOrder":0,"company":"Atomwise","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":1.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.02,"dosageForm":"","sponsorNew":"Atomwise \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/ Sanofi"},{"orgOrder":0,"company":"Atomwise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Atomwise

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Allosteric TYK2 inhibitor discovered by leveraging Atomwise’s proprietary AI drug discovery platform AtomNet®, into clinical trials, which is investigated for autoimmune disease.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 03, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The Atomwise approach shifts the mode of drug discovery away from serendipitous discovery and toward search based on structure, making the drug discovery process more rational, effective, and efficient.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $20.0 million

                          August 17, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Sanofi

                          Deal Size : $1,020.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : As part of the strategic partnership, Atomwise will work closely with the FutuRx management team, investors and incubated portfolio companies to apply its AI technology to early-stage drug discovery projects.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 18, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : FutuRx

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The grant funding will be used to discover novel compounds that can advance the development of novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the Gates Foundation’s global network of partners and funded investig...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 06, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : Bill & Melinda Gates Foundation

                          Deal Size : $2.3 million

                          Deal Type : Funding

                          blank